Erectile Dysfunction Drug Companies to Benefit from Largely Untapped Markets in Europe

20 September, 2005

Even with 30 million cases of erectile dysfunction (ED) registered in Europe, the infertility drugs market has not taken off to the expected extent in the region. The blame could lie largely with the conservative attitude regarding infertility among its people. While more than half of the men over 40 years of age suffer from this disorder, only 10 to 15 per cent seek treatment.

Drug companies can profit from these untapped markets by improving awareness in the target population. More men have already started consulting doctors, especially since ED is treatable at any stage.

There is also a high prevalence of ED in comorbid medical conditions and through associated risk factors such as cardiovascular diseases, hypertension, dyslipidemia and depression. Superior R&D and innovation-focused strategies will enable market participants to better harness the potential of this market.

Companies have to focus on product innovation and competitive pricing for better targeting of consumers and brand positioning. They should consider generic product development strategies to sustain their reputation in this field.

To know more read:
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-20-2005/0004110861&EDATE=